Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

GeneDx Holdings (WGS) Long-Term Investments (2020 - 2021)

GeneDx Holdings has reported Long-Term Investments over the past 2 years, most recently at $442.8 million for Q2 2021.

Quarterly Long-Term Investments changed N/A to $442.8 million in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $442.8 million through Jun 2021, changed N/A year-over-year, with the annual reading at $442.8 million for FY2020, N/A changed from the prior year.
Long-Term Investments was $442.8 million for Q2 2021 at GeneDx Holdings, roughly flat from $442.8 million in the prior quarter.
Over five years, Long-Term Investments peaked at $442.8 million in Q2 2021 and troughed at $442.8 million in Q3 2020.